Trials / Completed
CompletedNCT01667432
An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
A Multicenter, Prospective, Observational, Non-interventional Study Evaluating On-treatment Predictors of Response in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 141 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, multicenter, observational study will evaluate on-treatment predictors of response in patients with HBeAg positive or HBeAg negative chronic hepatitis B receiving treatment with peginterferon alfa-2a (PEGASYS®) in accordance with local labeling and the summary of product characteristics. Data will be collected from patients for the duration of their treatment and for up to 24 weeks thereafter.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peginterferon alfa-2a | Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes. |
Timeline
- Start date
- 2011-07-08
- Primary completion
- 2014-08-12
- Completion
- 2014-08-12
- First posted
- 2012-08-17
- Last updated
- 2017-04-10
- Results posted
- 2015-12-07
Locations
9 sites across 1 country: Bulgaria
Source: ClinicalTrials.gov record NCT01667432. Inclusion in this directory is not an endorsement.